Agilent Technologies Inc. today announced it has completed the
acquisition of Seahorse Bioscience, a leader in providing instruments
and assay kits for measuring cell metabolism and bioenergetics. Agilent
announced its intent to acquire Seahorse on Sept.
9.
Seahorse’s leading technology enables researchers to better understand
cell health, function and signaling, and how the cell may be impacted by
the introduction of a specific drug, by providing real-time kinetics to
unlock essential cellular bioenergetics data.
Agilent acquired Seahorse Bioscience because its unique technology
complements Agilent’s leading separations and mass spectrometry
solutions, in particular for metabolomics and disease research in pharma.
Scientists use Seahorse Bioscience’s proprietary XF Technology to
research the role of cell metabolism in neurodegeneration, aging,
cancer, cardiovascular disease, cell physiology, toxicology and
hepatobiology, immunology, infectious diseases, mitochondrial diseases,
model organisms, obesity, diabetes, metabolic disorders, screening and
translational medicine.
With the completion of the acquisition, most of the 200 employees who
were with Seahorse are now part of the Mass Spectrometry Division of
Agilent’s Life Sciences and Applied Markets Group.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences,
diagnostics and applied chemical markets, is the premier laboratory
partner for a better world. Agilent works with customers in more than
100 countries, providing instruments, software, services and consumables
for the entire laboratory workflow. The company generated revenues of
$4.0 billion in fiscal 2014 and employs about 12,000 people worldwide.
Agilent marks its 50th anniversary in analytical
instrumentation this year. Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151102005376/en/
Copyright Business Wire 2015